---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-006478"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:22:11.511669+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INBS Q2 FY2025 revenue falls 20% YoY; net loss widens to $2.26M; gross margin up 11pts

## Summary
- Revenue $607,494, down 20% YoY; net loss $2.25M vs $1.97M.
- Gross margin for six months improved to 38.5% from 27.7% on higher cartridge sales.
- FDA 510(k) submitted in Dec 2024; planning US market entry in 2025.
- Cash $2.24M; equity $4.20M as of Dec 31, 2024.
- Added 19 accounts; total 400+ active accounts in 19 countries.

## SEC filing metadata
- accession: 0001493152-25-006478
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315225006478/0001493152-25-006478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315225006478/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-006478
- JSON: https://secwatch.observer/filing/0001493152-25-006478.json
- Plain text: https://secwatch.observer/filing/0001493152-25-006478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.